Special Issue "Cardio-Oncology in Children"

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Oncology and Hematology".

Deadline for manuscript submissions: 20 December 2021.

Special Issue Editors

Dr. Vasu D. Gooty
E-Mail Website
Guest Editor
Division of Pediatric Cardiology, University of Tennessee Health Science Center, LeBonheur Children’s Hospital, 49N Dunlap Street, FOB Room - 358Memphis, TN 38015, USA
Interests: pediatric cardiology; pediatric echocardiography; cardiac MRI and cTA; pediatric cardio-oncology; machine learning and artificial intelligence; multisystem inflammatory syndrome in children—MIS-C
Prof. Dr. Jeffrey A. Towbin
E-Mail Website
Guest Editor
Division of Pediatric Cardiology, Department of Pediatrics, LeBonheur Children’s Hospital, University of Tennessee, Memphis, TN 38104, USA
Interests: diagnostic and therapeutic advances for cardiomyopathies; heart failure and heart transplantation; cardiovascular genetics; cardio-oncology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is with great pleasure that we invite you to collaborate and contribute to this Special Issue on “Cardio-Oncology in Children”. With rapid advancement in the treatment of pediatric cancer, the overall mortality from cancer has been drastically reduced. However, there is increased recognition of cardiovascular toxicity secondary to standard and new cancer therapeutic agents that leads to heart failure and associated complications. The incidence and prevalence of cardiotoxicity is seen as early as during the initial stages of therapy and as late as years after completing therapy, a group known as long-term survivors of childhood cancers. This can lead to significant morbidity and mortality from cardiovascular complications. Several surveillance and treatment guidelines for the management of these patients have been published in the last 5–10 years; however, most of this literature is based on expert opinion, observational studies in children and limited robust clinical trials.

In this Special Issue, we envision providing a broad perspective in the field of pediatric cardio-oncology and hope to shed light on critical unanswered questions surrounding the cardiovascular care of children with cancer with topics ranging from pathophysiology to the management of these children and future trends and goals. We invite authors to submit a topic-based manuscript that provides readers with an overview of the current state and future of pediatric cardio-oncology. Please consider participating.

We look forward to hearing from you regarding your potential contribution.

Dr. Vasu D. Gooty
Prof. Dr. Jeffrey A. Towbin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardio-oncology
  • heart failure
  • cancer
  • cardiomyopathy
  • cardiotoxicity
  • chemotherapy

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Management of Advanced Heart Failure in Children with Cancer Therapy-Related Cardiac Dysfunction
Children 2021, 8(10), 872; https://0-doi-org.brum.beds.ac.uk/10.3390/children8100872 - 30 Sep 2021
Viewed by 218
Abstract
The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, [...] Read more.
The evolution of cancer therapies has led to marked improvement in survival of those affected by childhood malignancies, while also increasing the recognition of early and late toxicities associated with cancer therapies. Cardiotoxicity can include cardiomyopathy/heart failure, coronary artery disease, stroke, pericardial disease, arrhythmias, and valvular and vascular dysfunction as a result of exposure to chemotherapy and/or radiation. Anthracyclines remain the most common cause of chemotherapy-induced cardiomyopathy (CCM) with varying clinical presentations including: acute, early onset, and late-onset. Many individuals develop cardiac dysfunction over the long-term, ranging from subclinical cardiac dysfunction to end-stage symptomatic heart failure. The focus of this review is on characterization of symptomatic heart failure in children with cancer therapy-related cardiac dysfunction (CTRCD) primarily due to CCM and utilization of advanced heart failure therapies, including ventricular assist device (VAD) support and heart transplantation, with consideration of unique patient-related factors. Full article
(This article belongs to the Special Issue Cardio-Oncology in Children)
Show Figures

Figure 1

Review
Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy
Children 2021, 8(9), 829; https://0-doi-org.brum.beds.ac.uk/10.3390/children8090829 - 21 Sep 2021
Viewed by 512
Abstract
Cardiotoxicity is a well-recognized late effect among childhood cancer survivors. With various pediatric cancers becoming increasingly curable, it is imperative to understand the disease burdens that survivors may face in the future. In order to prevent or mitigate cardiovascular complications, we must first [...] Read more.
Cardiotoxicity is a well-recognized late effect among childhood cancer survivors. With various pediatric cancers becoming increasingly curable, it is imperative to understand the disease burdens that survivors may face in the future. In order to prevent or mitigate cardiovascular complications, we must first understand the mechanistic underpinnings. This review will examine the underlying mechanisms of cardiotoxicity that arise from traditional antineoplastic chemotherapies, radiation therapy, hematopoietic stem cell transplantation, as well as newer cellular therapies and targeted cancer therapies. We will then propose areas for prevention, primarily drawing from the anthracycline-induced cardiotoxicity literature. Finally, we will explore the role of human induced pluripotent stem cell cardiomyocytes and genetics in advancing the field of cardio-oncology. Full article
(This article belongs to the Special Issue Cardio-Oncology in Children)
Show Figures

Figure 1

Back to TopTop